News

Article

EMA Recommends a Conditional Marketing Authorization for Kidney Transplant Medicine

The European Medicines Agency (EMA) has recommended a conditional marketing authorization be granted for Idefirix (imlinfidase) for the treatment of highly sensitized adult patients waiting for a kidney transplant.

The European Medicines Agency (EMA) has issued a statement, on June 26, 2020, recommending a conditional marketing authorization be granted for Idefirix (imlinfidase) for the treatment of highly sensitized adult patients waiting for a kidney transplant.

According to the recommendation, Idefirix should be used complementary to existing allocation programs for patients that have a very low chance of finding a matching kidney. Highly sensitized patients have elevated antibody levels making it more common for transplant rejection and therefore, the patients are deemed as ineligible for transplant. 

Idefirix is made of an enzyme that breaks down the antibodies produced by the patient. Through this mechanism, it is expected that the therapy will prevent the patient’s immune system from attacking the transplanted organ and ultimately reduce the risk of rejection.

The treatment has been supported through EMA’s Priority Medicines (PRIME) scheme, which supports medicines with the potential to address unmet medical needs. The conditional recommendation will be passed onto the European Commission for a decision on the adoption of marketing authorization throughout the European Union.

Source: EMA

 

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content